5-Amino-1MQ

Origin and a Note on Classification

5-Amino-1-methylquinolinium (5-amino-1MQ) is not a peptide at all — it is a small-molecule quinolinium-based inhibitor with a molecular weight of roughly 160 Da. It is included in the peptide wellness conversation because it targets the same adipose-tissue pathways that several metabolic peptides aim at, and because suppliers often cross-list it alongside research peptides. Anyone comparing it to compounds like AOD-9604 or tesofensine should understand at the outset that it is a different kind of molecule.

5-amino-1MQ emerged from academic medicinal-chemistry work on nicotinamide N-methyltransferase (NNMT) inhibitors. Notable publications from the Kraus lab at UT Southwestern and collaborators (2018 and following) characterized the compound's selectivity and in vivo effects in diet-induced obese mice.

Mechanism — NNMT Inhibition

NNMT is an enzyme that methylates nicotinamide using S-adenosylmethionine (SAM) as the methyl donor, producing 1-methylnicotinamide and S-adenosylhomocysteine. In adipose tissue, NNMT expression is elevated in obesity, and the enzyme is now understood to act as a metabolic rheostat: by consuming SAM and nicotinamide, it depletes both the cellular methylation capacity and the NAD+ salvage precursor pool. The downstream consequences most relevant to weight regulation are:

• Reduced NAD+ availability. With less nicotinamide salvaged back into the NAD+ pool, adipocyte sirtuin activity and oxidative metabolism decline.
• Altered methylation state. SAM depletion changes histone and cytosolic protein methylation patterns that influence adipocyte differentiation and lipid storage.
• Increased adipocyte energy expenditure. NNMT knockdown or inhibition in mice increases fatty-acid oxidation and browning markers in white adipose tissue.

5-amino-1MQ acts as a selective, cell-permeable NNMT inhibitor with reported IC50 values in the low micromolar range.

Evidence Base

The preclinical evidence is genuinely promising but almost entirely rodent-based. In diet-induced obese mice, 5-amino-1MQ administered for 11 days produced roughly 7% body-weight reduction and a ~35% reduction in white adipose tissue mass without altering food intake — an effect profile suggesting increased energy expenditure rather than appetite suppression. Subsequent studies have examined effects on muscle function in aged animals, with reports of improved muscle strength and mass attributed to reduced NNMT activity in skeletal muscle.

Human clinical data on 5-amino-1MQ is essentially absent as of early 2026. There are no completed FDA-registered clinical trials, no published peer-reviewed human pharmacokinetic studies, and no adequately powered efficacy trials. Everything known about the compound in humans comes from anecdotal use in the wellness market.

Practical Considerations

5-amino-1MQ is typically sold as an oral capsule (often 50–150 mg per capsule) by research-chemical and wellness suppliers. Community protocols suggest daily oral dosing for 2–3 month cycles. Because the human pharmacokinetic profile has not been published, the optimal dose, half-life, and target tissue exposure are all effectively unknown in humans.

Users sometimes stack it with GLP-1 agonists like semaglutide, on the theory that the two mechanisms are complementary — appetite suppression plus increased adipose energy expenditure. No trial has tested this combination.

Safety and Regulatory Status

5-amino-1MQ has no FDA approval for any indication and no established safety profile in humans. Rodent toxicology has not revealed major acute toxicities at studied doses, but chronic-use data is limited even in animals. Long-term NNMT inhibition raises theoretical concerns: NNMT plays roles beyond adipose tissue, including in liver one-carbon metabolism, and sustained systemic inhibition could have unintended consequences that short rodent studies would not detect.

The Bottom Line

5-amino-1MQ represents an interesting metabolic target validated in animal models, now marketed in humans well ahead of the clinical evidence. The NNMT mechanism is scientifically legitimate; the human dose-response, efficacy, and long-term safety are not yet characterized. For anyone tracking this space, the meaningful milestone to watch is the first published human pharmacokinetic or Phase 1 data.